Search Follow us


CO.DON is a leading manufacturer of autologous cell therapies for the treatment of cartilage defects. The company’s main product, Spherox, is based on the core spheroid technology and can repair cartilage defects of the knee of up to 10cm2 in a minimally invasive procedure. The Phase III clinical trial allowed CO.DON to obtain marketing authorisation from the European Medicine Agency (EMA) in July 2017, which opened access to all European markets. The company is preparing for the roll-out of Spherox and has already received a green light from the UK’s National Institute for Health and Care Excellence (NICE).

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs